Xeris Pharmaceuticals Stock Z Score
| XERS Stock | USD 3.29 0.05 1.50% |
Xeris | Z Score |
Xeris Pharmaceuticals Company Z Score Analysis
Xeris Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Xeris Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Xeris Pharmaceuticals is extremely important. It helps to project a fair market value of Xeris Stock properly, considering its historical fundamentals such as Z Score. Since Xeris Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xeris Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xeris Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
As per the company's disclosures, Xeris Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Xeris Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xeris Pharmaceuticals from analyzing Xeris Pharmaceuticals' financial statements. These drivers represent accounts that assess Xeris Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xeris Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 209.8M | 231.5M | 180.4M | 323.5M | 291.2M | 305.7M | |
| Enterprise Value | 230.6M | 307.6M | 256.5M | 485.3M | 436.8M | 458.6M |
Xeris Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xeris Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xeris Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xeris Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Xeris Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Xeris Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Xeris Pharmaceuticals' value.| Shares | Millennium Management Llc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Walleye Trading Advisors, Llc | 2024-09-30 | 1.1 M | Aqr Capital Management Llc | 2024-09-30 | 1.1 M | Redmile Group, Llc | 2024-09-30 | 1 M | Bank Of America Corp | 2024-09-30 | 1 M | D. E. Shaw & Co Lp | 2024-09-30 | 985 K | Goldman Sachs Group Inc | 2024-09-30 | 836.4 K | Kennedy Capital Management Inc | 2024-09-30 | 604.9 K | Blackrock Inc | 2024-09-30 | 10.7 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
Xeris Fundamentals
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 692.04 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.99 % | ||||
| Number Of Shares Shorted | 10.19 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 163.91 M | ||||
| Gross Profit | 152.44 M | ||||
| EBITDA | (23.73 M) | ||||
| Net Income | (62.26 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 229.19 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (47.02 M) | ||||
| Short Ratio | 6.21 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 4.77 | ||||
| Number Of Employees | 377 | ||||
| Beta | 1.29 | ||||
| Market Capitalization | 490.48 M | ||||
| Total Asset | 322.6 M | ||||
| Retained Earnings | (617.02 M) | ||||
| Working Capital | 61.07 M | ||||
| Net Asset | 322.6 M |
About Xeris Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.